Biome Australia Ltd (AU:BIO) has released an update.
Biome Australia Ltd has announced that it expects to surpass its upgraded FY24 revenue forecast of $12.5 million, marking a second consecutive quarter of positive cash flow and EBITDA. The company is preparing to launch its cholesterol-lowering probiotic, Biome Cholesterol™, in Q1 FY25, which has demonstrated a 14% reduction in cholesterol levels over a 12-week clinical trial. With strong growth and the upcoming product launch, Biome is optimistic about the financial outlook for the end of FY24 and the start of FY25.
For further insights into AU:BIO stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
